Telaprevir peaked and rapidly declined because the side effects were nasty and brutal; the dosing regimen was rigorous; and something far better could be seen on the horizon. With the newest treatments: side effect are minial, dosing is simple and there is not much better coming. There is no reason to expect the trajectory of the newer treatments to be similar to that of telaprevir.
Market Data 
Markets 
AI
